Priovant Selects Orsini Specialty Pharmacy as Distributor for FDA-Approved LISRAYA
FDA Approval and Product Differentiation
Priovant Therapeutics has selected Orsini Specialty Pharmacy as the specialty pharmacy partner for the U.S. distribution of LISRAYA (brepocitinib), which received FDA approval on August 27, 2026. LISRAYA is a once-daily oral therapy, 30mg, that selectively inhibits TYK2 and JAK1, and is the first oral treatment approved for adult dermatomyositis. The FDA granted it Orphan Drug Designation and Priority Review, and commercial supply began in the U.S. immediately following approval. This marks a commercial milestone by introducing dosing convenience and targeted immunomodulation into a market dominated by injectable therapies.
Clinical Value Demonstrated by VALOR
The Phase 3 VALOR study (NCT05437263), which formed the basis for approval, evaluated 241 adults randomized 1:1:1 to brepocitinib 30mg, 15mg, or placebo over 52 weeks. The 30mg dose group achieved a mean Total Improvement Score (TIS) of 46.5, significantly higher than 31.2 in the placebo group (p=0.0006). TIS40 response rates were 67.9% versus 44.3%, and the proportion achieving both TIS40 and oral steroid use of 2.5mg or less was 54.3% versus 26.6%. However, boxed warnings for major infections, malignancies, major cardiovascular events, and thrombosis remain, highlighting the need for JAK inhibitor prescribing caution and post-marketing monitoring.
Orsini's Role in Launch Execution
Orsini Specialty Pharmacy will support the transition from prescription to actual administration by connecting prescription receipt, insurance pre-authorization, patient education, and delivery. As an oral tablet, LISRAYA does not require cold chain logistics, and the core of this agreement is to secure a restricted distribution and accessibility infrastructure to reduce complex insurance reviews and patient attrition. Priovant's My Compass Support offers dedicated patient access specialists and insurance and financial assistance, reducing the monthly co-pay for eligible privately insured patients to as low as USD 0. The partnership is not a clinical asset transaction and is not classified as a financial licensing deal involving upfront, milestone, royalty, or equity payments.
Market and Competitive Landscape
The global dermatomyositis market is projected to reach USD 637.7M in 2026 and USD 931.6M in 2033, with approximately 50,000 adult patients in the U.S. The direct competitive standard of care is Octapharma's Octagam 10% (intravenous immune globulin human), approved by the FDA in July 2021 for adult dermatomyositis. Corticosteroids and immunosuppressants such as methotrexate and azathioprine are also widely used, but they carry long-term toxicity and high off-label prescribing reliance. LISRAYA's initial market penetration will depend not only on oral convenience but also on insurance coverage speed, patient selection due to boxed warnings, and the ability to overcome the established efficacy and physician experience of Octagam.
With FDA-approved LISRAYA immediately connected to Orsini's distribution network, Roivant Sciences (ROIV) has transitioned from R&D value to real-world prescription and revenue execution. In the Phase 3 VALOR trial, LISRAYA 30mg achieved a mean TIS of 46.5, surpassing the placebo's 31.2, providing a direct competitive basis against Octapharma's intravenous Octagam 10% in the USD 637.7M 2026 global dermatomyositis market. For researchers, the dual inhibition of TYK2 and JAK1 simultaneously improved skin and muscle function and steroid reduction, serving as a key signal for future indication development. For the industry, this case highlights how integrated specialty pharmacy operations for insurance approval and patient support can influence the speed of rare disease launches, with long-term commercial value needing to account for boxed warning management and sub-teens royalty payments to Pfizer (PFE) based on net sales milestones.
Source: PR Newswire Biotech (rss_filter)